Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display & Cocktail

62P - Genome-wide CRISPR gain of function screen reveals resistance mechanisms and potential therapeutic targets in PDK1-inhibited PDAC

Date

03 Mar 2025

Session

Poster Display & Cocktail

Presenters

Kevin Fink

Citation

Annals of Oncology (2025) 10 (suppl_2): 1-8. 10.1016/esmoop/esmoop104219

Authors

K. Fink1, K. Sleiman1, C. Veltkamp1, F. Wang1, M. Schmidt-Supprian2, G. Schneider3, D. Saur4

Author affiliations

  • 1 Translatum, Klinikum Rechts Der Isar, Institute of Translational Cancer Research and Experimental Cancer Therapy, 81675 - Munich/DE
  • 2 School Of Medicine, Technical University Munich, Translatum, Institute for Experimental Haematology, 81675 - Munich/DE
  • 3 Viszeral- Und Kinderchirurgie, UMG - Universitätsmedizin Göttingen, 37075 - Göttingen/DE
  • 4 Ii. Medizinische Klinik Und Poliklinik, Klinikum Rechts der Isar - Technische Universitaet Muenchen, 81675 - Munich/DE

Resources

This content is available to ESMO members and event participants.

Abstract 62P

Background

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a 5-year survival rate of 13%, mainly due to late diagnosis and treatment resistance. KRAS mutations play a central role in PDAC, and while the PI3K pathway and PDK1 can be targeted, resistance mechanisms limit treatment efficacy. Identifying these mechanisms is critical to improving therapies.

Methods

This study employed a robust genome-wide CRISPR activation (CRISPRa) gain-of-function screen to identify genetic pathways conferring resistance to PDK1 deletion in KRAS-driven PDAC. Using a CRISPRa SAM library of 23,439 genes, we activated genes in a KRASG12D-mutant murine PDAC cell line, assessing survival after PDK1 deletion via a Cre/loxP system, confirmed by PCR. Bioinformatics analysis then identified enriched pathways and key genetic drivers of resistance.

Results

The CRISPRa screen identified several resistance-associated signaling pathways, including ErbB, PI3K-AKT-mTOR, JAK/STAT, and Hippo/YAP1 pathways. Further pathway analysis revealed key genetic drivers, highlighting ErbB2/3, Rptor, Akt1, and Stat1. Conversely, TGF-beta signaling was depleted in PDK1-deleted cells. Targeting pathways like ErbB and PI3K-AKT-mTOR, both established in therapeutic contexts, could potentially synergistically enhance PDK1-targeted therapy efficacy. Preliminary data validate the role of mTOR signaling and TGF-beta’s impact on PDAC cell survival with PDK1 inhibition.

Conclusions

These findings provide valuable insights into the functional genetic basis of therapy resistance in PDAC. The identified pathways, including ErbB, PI3K-AKT-mTOR, JAK/STAT, Hippo/YAP1, and TGF-beta represent potential targets for combinatorial drug treatments to overcome resistance to PDK1 inhibition. Future work will focus on validating these targets through drug treatment assays and exploring their clinical relevance in improving PDAC treatment outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Technical University Munich, Munich, Germany.

Funding

The study was funded by the German Research Foundation and supported by the Else Kröner Promotionskolleg by the Technical University of Munich.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.